Pharsight

Drugs that contain Fulvestrant

1. Faslodex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8466139 ASTRAZENECA Formulation
Jan, 2021

(3 years ago)

US8329680 ASTRAZENECA Formulation
Jan, 2021

(3 years ago)

US6774122 ASTRAZENECA Formulation
Jan, 2021

(3 years ago)

US7456160 ASTRAZENECA Formulation
Jan, 2021

(3 years ago)

US6774122

(Pediatric)

ASTRAZENECA Formulation
Jul, 2021

(2 years ago)

US8466139

(Pediatric)

ASTRAZENECA Formulation
Jul, 2021

(2 years ago)

US8329680

(Pediatric)

ASTRAZENECA Formulation
Jul, 2021

(2 years ago)

US7456160

(Pediatric)

ASTRAZENECA Formulation
Jul, 2021

(2 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-725) Feb 19, 2019
New Indication(I-749) Aug 25, 2020
New Dosing Schedule(D-126) Sep 09, 2013
M(M-103) May 17, 2014
Pediatric Exclusivity(PED) Mar 09, 2014
M(M-123) Nov 09, 2015

Market Authorisation Date: 25 April, 2002

Treatment: Treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrin...

Dosage: SOLUTION;INTRAMUSCULAR

How can I launch a generic of FASLODEX before it's drug patent expiration?
More Information on Dosage

FASLODEX family patents

Family Patents

2. Fulvestrant patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833459 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(9 years from now)

US10188663 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(9 years from now)

US9271990 FRESENIUS KABI USA Fulvestrant formulations
May, 2034

(9 years from now)

Market Authorisation Date: 20 May, 2019

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Dosage: SOLUTION;INTRAMUSCULAR

More Information on Dosage

FULVESTRANT family patents

Family Patents